Sphere Fluidics closes $40m funding round

By Jane Byrne contact

- Last updated on GMT

© GettyImages/PonyWang
© GettyImages/PonyWang

Related tags: Cell line development, Cell therapy, genome editing

Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.

The round was led by France-based, Sofinnova Partners, and San Francisco’s Redmile Group, who co-invested on equal terms.

In conjunction with the financing, Sofinnova’s Tom Burt and Redmile Group’s Rob Faulkner will join the board of the UK firm.

Cyto-Mine
Cyto-Mine single cell analysis system © Sphere Fluidics

“We will use the funding to grow our sales force and service and support internationally. The funds will also enable development of new products and applications for our proprietary Cyto-Mine single cell analysis system and other new products,”​ Dr Frank Craig, CEO, Sphere Fluidics, told us. 

The company will also expand its product research and development programs.

Cell line, cell therapy development 

In 2018, Sphere Fluidics launched Cyto-Mine as its flagship product for the pharmaceutical and cell research industries market, to accelerate biopharmaceutical discovery and development.

To date, the technology has been purchased by an international customer base including global pharmaceutical companies, biotech, CDMOs, and leading research institutions, reported the UK developer.

The CEO outlined how Cyto-Mine is designed to process millions of samples per day, assessing and isolating rare or valuable cell variants or biological products, to simplify and improve throughput across antibody discovery, cell line development and cell therapy development. 

The system, he added, integrates isolation, selective screening, sorting, and imaging into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value cells to be captured in a single run.

“Earlier this year, we announced the Cyto-Mine’s new simplified design, enabling users to access additional functionalities through a more advanced and reliable system, to further streamline drug discovery workflows. The funding raised will support the technology’s further applications into new research areas such as cell therapy, synthetic biology and genome editing, in addition to ongoing enhancements of the platform’s capabilities and performance,” ​reported Craig.

Related news

Related products

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers